Brief: Fate Therapeutics Announces Treatment Of First Patient In Landmark Phase 1 Clinical Trial Of FT819, The First-Ever IPSC-Derived Car T-Cell Therapy
02/08/2021 22:17
Aug 2 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES TREATMENT OF FIRST PATIENT IN
LANDMARK PHASE 1 CLINICAL TRIAL OF FT819, THE FIRST-EVER
IPSC-DERIVED CAR T-CELL THERAPY
Source text for Eikon: ID:nGNX6VHtlt
Further company coverage: FATE.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview